Phase I/II Study of MLN8237 in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Trial Profile

Phase I/II Study of MLN8237 in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Alisertib (Primary) ; Irinotecan; Temozolomide
  • Indications Neuroblastoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 01 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top